Welcome - Home - Register - Login - Help/FAQ - 0 items

Search Enter keywords, a title or a report id number below. In All Categories --------------------- Telecom & Computing Business & Finance Mfg & Construction Pharma & Healthcare Consumer & Retail Gov & Public Sector Energy & Transport Country Reports Company Reports --------------------- Transcripts Advanced      Direct to Consumer Communication in the Pharmaceutical Industry The Royalty Rate Report 2010: A Comprehensive Assessment of ... The Biochemistry of Drug Metabolism: Two Volume Set      Select a currency for use throughout the site Australia Dollars Canada Dollars Euro Japan Yen Sweden Kroner Switzerland Francs UK Pounds US Dollars Viewing a category Home  - Pharmaceuticals      - You are in Companies category    Sort by    Report Name ASC Report Name DESC Report Price ASC Report Price DESC   Sorted by Date Added Merck KGaA: Pipeline, Products, Performance and Potential Espicom Business Intelligence Ltd, June 2009, Pages: 144 With a tradition of over three hundred years, Merck KGaA is one of the oldest pharmaceutical and chemical companies in the world Merck has 192 companies in 60 countries, which employ over 30,000 perso... Who Owns You? The Corporate Gold Rush to Patent Your Genes John Wiley and Sons Ltd, Feb 2009, Pages: 200 Surely you own your own genes, don't you? Think again Now that the race to map the human genome is over, another competition has ensued Biotech companies, universities, and research institutions, sens... Competitor Analysis: C5a-R Antagonists La Merie, Jan 2009, Pages: 11 The present Competitive Intelligence Report about Complement C5a & C5a Receptor Antagonists provides a competitor evaluation in the field of R&D projects of antagonists used to interfere with the inte... The Top Five Global Pharma Companies; Where they are Now and Where they heading? i3 Consult, Dec 2008, Pages: 25 A mini report identifying drivers and barriers to sustaining financial performance over the next 5 years for the top five global pharmaceutical companies -Johnson & Johnson, Pfizer, GSK, Novartis and ... Emerging Blockbusters: 2009's Most Promising Drugs and the Future of the Blockbuster Model Decision Resources, Inc., Dec 2008, Pages: 27 Introduction In 2007, 93 blockbuster drugs (drugs with more than $1 billion in annual sales) were on the market and generated more than $220 billion in revenue These high-value products are fundamenta... What to Do When the R&D Pipeline Runs Dry Decision Resources, Inc., Sep 2008, Pages: 26 The pharmaceutical industry has been coping with declining R&D productivity for more than two decades and is under significant pressure to improve its bottom line and growth prospects Industry stakeho... PharmaDeals®: Deal Making Spotlight on Sanofi-Aventis PharmaVentures, April 2006, Pages: 301 One of a set of 5 reports detailing the deal making activities of the top 5 pharmaceutical companies, from 2000 up to and including the whole of 2005, if you are looking to partner with big pharma, th... PharmaDeals®: Deal Making Spotlight on Pfizer PharmaVentures, April 2006, Pages: 371 One of a set of 5 reports detailing the deal making activities of the top 5 pharmaceutical companies, from 2000 up to and including the whole of 2005, if you are looking to partner with big pharma, th... Directory of Clinical Research Companies in India CYGNUS Business Consulting & Research, Feb 2008, Pages: 143 India is fast emerging as a favoured destination for clinical trials by global pharmaceutical and biotech companies that are looking for partnerships or setting up new operations Two major reasons for... AstraZeneca: Pipeline, Products, Performance, Potential Espicom Business Intelligence Ltd, Oct 2009, Pages: 172 Pharmaceutical company intelligence reports from Espicom provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial perform... MedImmune Inc.: PharmaVitae Profile Datamonitor, Nov 2007, Pages: 120 Introduction This analysis examines the historical and forecast performance for MedImmune in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline... Shire: Pipeline, Products, Performance and Potential Espicom Business Intelligence Ltd, Aug 2009, Pages: 80 In the last five years, Shire has spent over US$8 billion on acquisitions which have seen the company considerably expand its global presence and areas of interest Most importantly, these acquisitions... Monoclonal Antibodies Report Part II: Companies - Holding mAbs in portfolio promises protection against the looming 2011-12 patent cliff Datamonitor, Sep 2007, Pages: 277 Introduction This report provides a comprehensive strategic analysis of the mAb market out to 2012 by company It identifies four established and four emerging players within the mAb sector which are f... Trends in the Commercialization of Biomarkers: Tests and Companies Decision Resources, Inc., Oct 2007, Pages: 28 As health care moves toward personalized medicine, biomarkers have gained an increasingly important role in the delivery of efficient, quality care The FDA has established specific definitions for bio... Does the Treatment of Huntington's Disease Represent a Commercial Opportunity? Decision Resources, Inc., Aug 2007, Pages: 22 Huntington’s disease (HD) is a genetic neurological disorder characterized by uncontrolled body movements and cognitive dysfunction No drugs are approved to treat the disorder, leaving a high level of... E7: The Outlook for Pharmaceuticals to 2012 Espicom Business Intelligence Ltd, Sep 2009 E7: The Outlook for Pharmaceuticals to 2012 is a new collection of management reports from Espicom Business Intelligence. Each report provides an individual and highly-detailed analysis of each marke... Kyowa Hakko: Performance, Products, Pipeline and Potential Espicom Business Intelligence Ltd, Aug 2009, Pages: 84 In Japan, recent shifts in the economic environment have increased competition for domestic pharmaceuticals as the larger pharma companies from Europe and the US are afforded more and more of the Japa... Johnson & Johnson: Performance, Products, Pipeline and Potential Espicom Business Intelligence Ltd, Aug 2009, Pages: 182 Johnson & Johnson operates in nearly all markets worldwide and has developed a substantial infrastructure consisting of over 230 companies active in all fields of healthcare In 2008, J&J achieved reco... Gilead Sciences: Pipeline - Products - Performance - Potential Espicom Business Intelligence Ltd, Feb 2009, Pages: 78 In 2006, Gilead took a gamble, believing the short-term costs incurred through the acquisitions of Corus Pharma, Myogen and Raylo Chemicals would lead to long-term growth for the company The consequen... Chugai: Pipeline, Products, Performance and Potential Espicom Business Intelligence Ltd, Oct 2009, Pages: 80 Pharmaceutical company intelligence reports from Espicom provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial perform... Results:  First -   Prev -   1 -   2 -   3 -   4 -   5 -   6 -   Next -   Last

		Top of page

All rights reserved. © Copyright 2009 Research and Markets1    Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster